Lymphomas
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
- Details
ClinicalTrials.gov ID:
NCT01716806
Diagnosis Type:
Non-Hodgkins
USOR Number:
- Address
1448 East Common St
New
Braunfels, TX 78130
P: (830) 643-1762